Immunome, a company in the biotech sector, recently completed a secondary offering of 19.35 million shares. The shares were priced at $7.75 each. This pricing and the volume of shares sold provide a clear snapshot of the company’s current market strategy and investor interest. The total value of the offering, calculated by multiplying the number of shares by the price per share, comes out to approximately $150 million. This figure represents a significant capital influx for Immunome, potentially earmarked for research, development, or expansion efforts. The offering’s size and pricing are key statistics that investors and market analysts will watch closely to gauge the company’s future performance and market positioning.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
![[Webinar] Combatting SARS-CoV-2 Variants: Neutralization Testing from Alpha to Mu](https://i.ytimg.com/vi/lR-T2thFZ1w/mqdefault.jpg)
